Cisatracurium
سیسآتراکوریوم
🦴 Musculo-Skeletal SystemNon-depolarising neuromuscular blocker (benzylisoquinolinium)
Market / country: 🇺🇸 USA
Nimbex (US)
🧮 Dose calculator
Tracheal intubation and neuromuscular blockade · Regimen source: FDA Cisatracurium · 2.2
- • Maintenance 0.03 mg/kg, first at 40–50 min after 0.15 mg/kg. Infants 1–23 months: 0.15 mg/kg. Burns: resistance (higher doses). Monitor with a nerve stimulator. FDA Cisatracurium · 2.3FDA Cisatracurium · 2.2FDA Cisatracurium · 2.4FDA Cisatracurium · 2
- • Only by personnel trained in anaesthesia, with airway, ventilation and resuscitation equipment at hand. FDA Cisatracurium · 2
Enter age and weight.
🛡️ Safety & information
Contraindications
- ⛔ Known hypersensitivity to cisatracurium. FDA Cisatracurium · 4
Warnings
- • Only with ventilatory support available; does not cause unconsciousness (adequate anaesthesia required); anaphylaxis; residual paralysis — monitor with a peripheral nerve stimulator. FDA Cisatracurium · 5
- • Fatal medication errors (separate storage and labelling); seizures (laudanosine); malignant hyperthermia. FDA Cisatracurium · 5
Formulations
- 10 mg/mL (200 mg/20 mL) — injection 🇺🇸 USA FDA Cisatracurium · 3
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Cisatracurium · 8.1
“Risk Summary The 10 mL Cisatracurium Besylate Injection multiple-dose vials contain the preservative benzyl alcohol.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Cisatracurium · 8.2
“Risk Summary The 10 mL Cisatracurium Besylate Injection multiple-dose vials contain the preservative benzyl alcohol.”
- 👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Cisatracurium · 8.4
“The safety and effectiveness of Cisatracurium Besylate Injection have not been established in pediatric patients less than 1 month of age.”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Cisatracurium · 8.5
“Of the total number of subjects (135) in clinical studies of Cisatracurium Besylate Injection, 57, 63, and 15 subjects were 65 to 70 years old, 70 to 80 years old, and greater than 80 years old, respectively.”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)ANDA216539
- DailyMed (FDA label)FDA Cisatracurium
- MedlinePlus (NIH)❌ None
- WHO ATC/DDDM03AC11
- Darooyab (Iran)❌ None
🇮🇷 Not found in Iran list Darooyab · search
Darooyab lists no registered dosage form or brand for this drug. This does not prove it is unavailable.
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Cisatracurium · 3FDA Cisatracurium · 2.2FDA Cisatracurium · 2.3FDA Cisatracurium · 2.4FDA Cisatracurium · 2FDA Cisatracurium · 4FDA Cisatracurium · 5FDA Cisatracurium · SPL approval / marketing categoryFDA Cisatracurium · 8.1FDA Cisatracurium · 8.2FDA Cisatracurium · 8.4FDA Cisatracurium · 8.5
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · search
- Clinical review⚠ Unverified